Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Estimating Direct Cost of Cystic Fibrosis Care Using Irish Registry Healthcare Resource Utilisation Data, 2008-2012.

PharmacoEconomics - 1 Oct 2017

Jackson Abaigeal D, Jackson Andrew L, Fletcher Godfrey, Doyle Gerardine, Harrington Mary, Zhou Shijun, Cullinane Fiona, Gallagher Charles, McKone Edward

Abstract excerpt

BACKGROUND: Understanding the determinants of cost of cystic fibrosis (CF) care and health outcomes may be useful for financial planning for the delivery of CF services. Registries contain information otherwise unavailable to healthcare activity/cost monitoring systems. We estimated the direct medical cost of CF care using registry data and examined how cost was affected by patient characteristics and CF gene (CF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Comorbidity
Share to Cystic Fibrosis Transmembrane Conductance Regulator

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Costs

Share to Health Care Costs

Share to Hospitalization

Share to Models, Economic

Share to Patient Acceptance of Health Care

Share to Registries

Source

Identifiers

PMID: 28699086
DOI: 10.1007/s40273-017-0530-4

Genes

CFTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Estimating Direct Cost of Cystic Fibrosis Care Using Irish Registry Healthcare Resource Utilisation Data, 2008-2012.PMID 28699086Read ↗

Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials.Semantic proximity Read ↗

Non-pulmonary chronic diseases in adults with cystic fibrosis: analysis of data from the Cystic Fibrosis Registry.Semantic proximity Read ↗

Neonatal screening programme for CF: Results from the Irish Comparative Outcomes Study (ICOS).Semantic proximity Read ↗

Ivacaftor for cystic fibrosis: An evaluation of real world utilisation and expenditure in the Irish Healthcare Setting.Semantic proximity Read ↗

Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis.Semantic proximity Read ↗

Medical Costs of Alpha-1 Antitrypsin Deficiency-Associated COPD in the United StatesSemantic proximity Read ↗

Comparison of the US and Australian cystic fibrosis registries: the impact of newborn screening.Semantic proximity Read ↗

Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis.Semantic proximity Read ↗

Forecasting the Long-Term Clinical and Economic Outcomes of Lumacaftor/Ivacaftor in Cystic Fibrosis Patients with Homozygous phe508del Mutation.Semantic proximity Read ↗

Cost-effectiveness of newborn screening for cystic fibrosis determined with real-life data.Semantic proximity Read ↗

Current prices versus minimum costs of production for CFTR modulatorsSemantic proximity Read ↗

Inpatient admissions and costs for adolescents and young adults with congenital heart defects in New York, 2009-2013Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.